Obesity is on the rise worldwide and is related to the incidence of colon cancer , but its mechanism has been a mystery. In a new study, Yale University research discovered how obesity drives tumor growth in mice and revealed potential strategies to combat this cancer pathogenesis.
The team studied mice implanted with genetic models of tumors or colon cancer. The researchers first studied the effect of a high-fat diet on mice. Then they gave the mice one of two drugs: one was the controlled release mitochondrial proton mass (CRMP), and the other was metformin (the world’s most commonly used diabetes prescription drug), which burns fat in the liver drug.
The team found that high levels of insulin are the link between obesity and kenza yemaroni. Insulin increases glucose uptake in tumors and promotes tumarara growth. The researchers also found that both drugs can reduce insulin levels and slow tumor growth in mice.
The researchers say that this study is the first to demonstrate that obesity-induced high insulin levels drive colon cancer by increasing glucose uptake in these models. Although further research is needed to confirm whether these findings are applicable to humans, insulin reduction therapy: metformin, CRMP , And even exercise can help slow or prevent colon cancer.
